Virtual Screening as a Strategy for the Identification of Xenobiotics Disrupting Corticosteroid Action

PLoS ONE

Volumn 7, Issue 10, 2012, Pages

  Nashev, Lyubomir G ^a   Vuorinen, Anna ^b   Praxmarer, Lukas ^b   Chantong, Boonrat ^a   Cereghetti, Diego ^a   Winiger, Rahel ^a   Schuster, Daniela ^b   Odermatt, Alex ^a  

^a UNIVERSITY OF BASEL   (Switzerland)

^b UNIVERSITY OF INNSBRUCK   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 2; AB 110873; CHEMICAL COMPOUND; CORTICOSTEROID; CORTISONE; ENDOCRINE DISRUPTOR; GLUCOCORTICOID; HYDROCORTISONE; INTERLEUKIN 6; LASALOCID; MINERALOCORTICOID RECEPTOR; REACTIVE OXYGEN METABOLITE; SILANE DERIVATIVE; UNCLASSIFIED DRUG; XENOBIOTIC AGENT;

ANIMAL CELL; ARTICLE; BIOASSAY; CHEMICAL ANALYSIS; CHEMICAL STRUCTURE; COMPUTER MODEL; CONCENTRATION RESPONSE; CORTICOSTEROID METABOLISM; CYTOKINE PRODUCTION; HORMONE ACTION; HUMAN; HUMAN CELL; MOLECULAR LIBRARY; NONHUMAN; PHARMACOPHORE; PLACENTA; PREDICTION; SCREENING; TOXICITY TESTING; VIRTUAL REALITY; VIRTUAL SCREENING;

11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1; 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 2; ADRENAL CORTEX HORMONES; ANIMALS; BIOLOGICAL ASSAY; CERCOPITHECUS AETHIOPS; COS CELLS; DATABASES, PHARMACEUTICAL; DRUG EVALUATION, PRECLINICAL; ENDOCRINE DISRUPTORS; GENE EXPRESSION REGULATION; HEK293 CELLS; HUMANS; INTERLEUKIN-6; MICROGLIA; MITOCHONDRIA; MOLECULAR DOCKING SIMULATION; PROTEIN CONFORMATION; RECEPTORS, MINERALOCORTICOID; SILANES; SUPEROXIDES; USER-COMPUTER INTERFACE; XENOBIOTICS;

EID: 84867137068     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0046958     Document Type: Article

References (51)

1. Diamanti-Kandarakis E, Bourguignon JP, Giudice LC, Hauser R, Prins GS, et al. (2009) Endocrine-disrupting chemicals: an Endocrine Society scientific statement. Endocr Rev 30: 293-342.
2. Neel BA, Sargis RM, (2011) The paradox of progress: environmental disruption of metabolism and the diabetes epidemic. Diabetes 60: 1838-1848.
3. Allera A, Lo S, King I, Steglich F, Klingmuller D, (2004) Impact of androgenic/antiandrogenic compounds (AAC) on human sex steroid metabolizing key enzymes. Toxicology 205: 75-85.
4. Luccio-Camelo DC, Prins GS, (2011) Disruption of androgen receptor signaling in males by environmental chemicals. J Steroid Biochem Mol Biol 127: 74-82.
5. Schug TT, Janesick A, Blumberg B, Heindel JJ, (2011) Endocrine disrupting chemicals and disease susceptibility. J Steroid Biochem Mol Biol 127: 204-215.
6. Odermatt A, Gumy C, (2008) Glucocorticoid and mineralocorticoid action: why should we consider influences by environmental chemicals? Biochem Pharmacol 76: 1184-1193.
7. Ma X, Lian QQ, Dong Q, Ge RS, (2011) Environmental inhibitors of 11β-hydroxysteroid dehydrogenase type 2. Toxicology 285: 83-89.
8. Briet M, Schiffrin EL, (2010) Aldosterone: effects on the kidney and cardiovascular system. Nat Rev Nephrol 6: 261-273.
9. Hadoke PW, Iqbal J, Walker BR, (2009) Therapeutic manipulation of glucocorticoid metabolism in cardiovascular disease. Brit J Pharmacol 156: 689-712.
10. Lastra G, Dhuper S, Johnson MS, Sowers JR, (2010) Salt, aldosterone, and insulin resistance: impact on the cardiovascular system. Nat Rev Cardiol 7: 577-584.
11. Messaoudi S, Azibani F, Delcayre C, Jaisser F, (2012) Aldosterone, mineralocorticoid receptor, and heart failure. Mol Cell Endocrinol 350: 266-272.
12. Groeneweg FL, Karst H, de Kloet ER, Joels M, (2012) Mineralocorticoid and glucocorticoid receptors at the neuronal membrane, regulators of nongenomic corticosteroid signalling. Mol Cell Endocrinol 350: 299-309.
13. Gomez-Sanchez EP, Gomez-Sanchez CE, (2012) Central regulation of blood pressure by the mineralocorticoid receptor. Mol Cell Endocrinol 350: 289-298.
14. Odermatt A, Kratschmar DV, (2012) Tissue-specific modulation of mineralocorticoid receptor function by 11β-hydroxysteroid dehydrogenases: An overview. Mol Cell Endocrinol 350: 168-186.
15. Edwards CR, Stewart PM, Burt D, Brett L, McIntyre MA, et al. (1988) Localisation of 11β-hydroxysteroid dehydrogenase-tissue specific protector of the mineralocorticoid receptor. Lancet 2: 986-989.
16. Funder JW, Pearce PT, Smith R, Smith AI, (1988) Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated. Science 242: 583-585.
17. Mune T, Rogerson FM, Nikkila H, Agarwal AK, White PC, (1995) Human hypertension caused by mutations in the kidney isozyme of 11β-hydroxysteroid dehydrogenase. Nat Genet 10: 394-399.
18. Wilson RC, Harbison MD, Krozowski ZS, Funder JW, Shackleton CH, et al. (1995) Several homozygous mutations in the gene for 11β-hydroxysteroid dehydrogenase type 2 in patients with apparent mineralocorticoid excess. J Clin Endocrinol Metab 80: 3145-3150.
19. Ferrari P, (2010) The role of 11β-hydroxysteroid dehydrogenase type 2 in human hypertension. Biochim Biophys Acta 1802: 1178-1187.
20. Lindsay RS, Lindsay RM, Edwards CR, Seckl JR, (1996) Inhibition of 11β-hydroxysteroid dehydrogenase in pregnant rats and the programming of blood pressure in the offspring. Hypertension 27: 1200-1204.
21. Benediktsson R, Calder AA, Edwards CR, Seckl JR, (1997) Placental 11β-hydroxysteroid dehydrogenase: a key regulator of fetal glucocorticoid exposure. Clin Endocrinol 46: 161-166.
22. Deuchar GA, McLean D, Hadoke PW, Brownstein DG, Webb DJ, et al. (2011) 11β-hydroxysteroid dehydrogenase type 2 deficiency accelerates atherogenesis and causes proinflammatory changes in the endothelium in apoe-/- mice. Endocrinology 152: 236-246.
23. Schuster D, (2010) 3D pharmacophores as tools for activity profiling. Drug Discov Today Technol 7: 205-211.
24. Wermuth CG, Ganellin CR, Lindberg P, Mitscher LA, (1998) Pure Appl Chem. 70: 1129-1143.
25. Duwensee K, Schwaiger S, Tancevski I, Eller K, van Eck M, et al. (2011) Leoligin, the major lignan from Edelweiss, activates cholesteryl ester transfer protein. Atherosclerosis 219: 109-115.
26. Markt P, Feldmann C, Rollinger JM, Raduner S, Schuster D, et al. (2009) Discovery of Novel CB(2) Receptor Ligands by a Pharmacophore-Based Virtual Screening Workflow. J Med Chem 52: 369-378.
27. Schuster D, Markt P, Grienke U, Mihaly-Bison J, Binder M, et al. (2011) Pharmacophore-based discovery of FXR agonists. Part I: Model development and experimental validation. Bioorg Med Chem 19: 7168-7180.
28. Hein M, Zilian D, Sotriffer CA, (2010) Drug Discov Today Technol. 7: 229-236.
29. Schuster D, Kowalik D, Kirchmair J, Laggner C, Markt P, et al. (2011) Identification of chemically diverse, novel inhibitors of 17β-hydroxysteroid dehydrogenase type 3 and 5 by pharmacophore-based virtual screening. J Steroid Biochem Mol Biol 125: 148-161.
30. Nashev LG, Schuster D, Laggner C, Sodha S, Langer T, et al. (2010) The UV-filter benzophenone-1 inhibits 17β-hydroxysteroid dehydrogenase type 3: Virtual screening as a strategy to identify potential endocrine disrupting chemicals. Biochem Pharmacol 79: 1189-1199.
31. Schuster D, Maurer EM, Laggner C, Nashev LG, Wilckens T, et al. (2006) The discovery of new 11β-hydroxysteroid dehydrogenase type 1 inhibitors by common feature pharmacophore modeling and virtual screening. J Med Chem 49: 3454-3466.
32. Diederich S, Grossmann C, Hanke B, Quinkler M, Herrmann M, et al. (2000) In the search for specific inhibitors of human 11β-hydroxysteroid-dehydrogenases (11β-HSDs): chenodeoxycholic acid selectively inhibits 11β-HSD-I. Eur J Endocrinol 142: 200-207.
33. Classen-Houben D, Schuster D, Da Cunha T, Odermatt A, Wolber G, et al. (2009) Selective inhibition of 11β-hydroxysteroid dehydrogenase 1 by 18α-glycyrrhetinic acid but not 18β-glycyrrhetinic acid. J Steroid Biochem Mol Biol 113: 248-252.
34. Kim CH, Ramu R, Ahn JH, Bae MA, Cho YS, (2010) Fenofibrate but not fenofibric acid inhibits 11β-hydroxysteroid dehydrogenase 1 in C2C12 myotubes. Mol Cell Biochem 344: 91-98.
35. Atanasov AG, Tam S, Rocken JM, Baker ME, Odermatt A, (2003) Inhibition of 11β-hydroxysteroid dehydrogenase type 2 by dithiocarbamates. Biochem Biophys Res Commun 308: 257-262.
36. Luther JM, Gainer JV, Murphey LJ, Yu C, Vaughan DE, et al. (2006) Angiotensin II induces interleukin-6 in humans through a mineralocorticoid receptor-dependent mechanism. Hypertension 48: 1050-1057.
37. Frieler RA, Meng H, Duan SZ, Berger S, Schutz G, et al. (2011) Myeloid-specific deletion of the mineralocorticoid receptor reduces infarct volume and alters inflammation during cerebral ischemia. Stroke 42: 179-185.
38. Bledsoe RK, Madauss KP, Holt JA, Apolito CJ, Lambert MH, et al. (2005) A ligand-mediated hydrogen bond network required for the activation of the mineralocorticoid receptor. J Biol Chem 280: 31283-31293.
39. Matinlinna J, Ozcan M, Lassila L, Kalk W, Vallittu P, (2008) Effect of the cross-linking silane concentration in a novel silane system on bonding resin-composite cement. Acta Odontol Scand 66: 250-255.
40. Seppa L, (2004) Fluoride varnishes in caries prevention. Med Princ Pract 13: 307-311.
41. Friedman A, Friedman J, (2009) New biomaterials for the sustained release of nitric oxide: past, present and future. Exp Opin Drug Deliv 6: 1113-1122.
42. Pan G, Schaefer DW, Ilavsky J, (2006) Morphology and water barrier properties of organosilane films: the effect of curing temperature. J Colloid Interface Sci 302: 287-293.
43. McCurley A, Jaffe IZ, (2012) Mineralocorticoid receptors in vascular function and disease. Mol Cell Endocrinol 350: 256-265.
44. Young MJ, Rickard AJ, (2012) Mechanisms of mineralocorticoid salt-induced hypertension and cardiac fibrosis. Mol Cell Endocrinol 350: 248-255.
45. Bocchini V, Mazzolla R, Barluzzi R, Blasi E, Sick P, et al. (1992) An immortalized cell line expresses properties of activated microglial cells. J Neurosci Res 31: 616-621.
46. Kratschmar DV, Vuorinen A, Da Cunha T, Wolber G, Classen-Houben D, et al. (2011) Characterization of activity and binding mode of glycyrrhetinic acid derivatives inhibiting 11β-hydroxysteroid dehydrogenase type 2. J Steroid Biochem Mol Biol 125: 129-142.
47. Wolber G, Langer T, (2005) LigandScout: 3-D pharmacophores derived from protein-bound ligands and their use as virtual screening filters. J Chem Inf Model 45: 160-169.
48. Huang N, Shoichet BK, Irwin JJ, (2006) Benchmarking sets for molecular docking. J Med Chem 49: 6789-6801.
49. Schuster D, Laggner C, Steindl TM, Palusczak A, Hartmann RW, et al. (2006) Pharmacophore modeling and in silico screening for new P450 19 (aromatase) inhibitors. J Chem Inf Model 46: 1301-1311.
50. Verdonk ML, Cole JC, Hartshorn MJ, Murray CW, Taylor RD, (2003) Improved protein-ligand docking using GOLD. Proteins 52: 609-623.
51. Jones G, Willett P, Glen RC, Leach AR, Taylor R, (1997) Development and validation of a genetic algorithm for flexible docking. J Mol Biol 267: 727-748.